Skip to main content

Advertisement

Table 3 Pharmacological agents targeting VM

From: Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin

Therapeutic agents Molecular target or function Effect on VM References
Bevacizumab (Avastin) VEGF no effect [114]
PARP inhibition VE-cadherin inhibition [127]
Thalidomide (Thalomid) TNFα; ROS producer inhibition [147]
TNP-470 (AGM-1470) TK inhibition no effect [148]
Endostatin (rhEndostatin, Endostar) integrin signaling no effect [149]
Rapamycin (Rapamune) mTOR, VEGF inhibition [150]
Curcumin EPHA2, PI3K, MMPs inhibition [151]
Isoxanthohumol TGF-β signaling inhibition [152]
Vadimezan (ASA404, AS1404, DMXAA) MAPK, VE-cadherin inhibition [140]
Resveratrol VEGF-R1, VEGF-R2 inhibition [153]
Ginsenoside Rg3 VE-cadherin/MMPs/EPHA2 inhibition [154]